Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy

Personalized medicine in treating pancreatic ductal adenocarcinoma (PDAC) is still in its infancy, albeit PDAC-related deaths are projected to rise over the next decade. Only recently, maintenance therapy with the PARP inhibitor olaparib showed improved progression-free survival in germline BRCA1/2-...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cells
Autori principali: Roger, Elodie, Gout, Johann, Arnold, Frank, Beutel, Alica K., Müller, Martin, Abaei, Alireza, Barth, Thomas F. E., Rasche, Volker, Seufferlein, Thomas, Perkhofer, Lukas, Kleger, Alexander
Natura: Artigo
Lingua:Inglês
Pubblicazione: MDPI 2020
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7563330/
https://ncbi.nlm.nih.gov/pubmed/32948057
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cells9092110
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi